WuXi AppTec acquires US-based CRO noting recent Chinese regulatory reforms

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/psisa)
(Image: Getty/psisa)

Related tags: Wuxi apptec, Clinical trial

WuXi AppTec’s acquisition of ResearchPoint Global (RPG) follows the release of a new guideline that will enable Chinese companies to accept clinical trial data from other countries.

The guideline was issued last week​ in a move to reform the management of clinical trials in the country.

WuXi cited the recent regulatory changes in its announcement of the acquisition, noting the opportunities presented by the reform.

According to the company, the acquisition is a strategic step forward to expand its clinical research capabilities in the US and globally.

The Austin, Texas-headquartered contract clinical research organization will operate as a wholly-owned subsidiary of WuXi. WuXi’s China-based Clinical Development Service (CDS) team will be integrated into the new business unit.

Dr. Ge Li WuXi AppTec chairman and CEO commented in a press release: "This business combination lays the groundwork for the creation of an integrated global clinical service organization with global expertise and global network."

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars